Ministry of Justice and Mashroat sign MoU

The MoU was signed by Undersecretary for Joint Services at the Ministry of Justice Abdulrahman Al-Khorayef and Secretary General of the Board of Directors and Director General of Mashroat Ahmed bin Motair Al-Balawi.
Updated 06 May 2019

Ministry of Justice and Mashroat sign MoU

The Ministry of Justice and the National Program to Support the Management of Projects in Public Entities (Mashroat) have signed a memorandum of understanding, whereby Mashroat will provide consultancy and technical support services to increase the effectiveness, efficiency and sustainability of national infrastructure projects, in line with the goals of the Saudi Vision 2030.
The MoU was signed by Undersecretary for Joint Services at the Ministry of Justice Abdulrahman Al-Khorayef and Secretary General of the Board of Directors and Director General of Mashroat Ahmed bin Motair Al-Balawi. Also present at the signing ceremony were Deputy Minister of Justice Shaikh Saad bin Mohammed Al-Saif and Assistant Minister of Economy and Planning Khalid bin Saud Al-Shunaifi.
Al-Khorayef said: “The MoU supports the ministry’s drive to ensure that all projects are managed and delivered on time and to the highest standards and specifications by bolstering partnerships with national sectors, agencies and programs. In addition, it affirms the ministry’s commitment to constructive collaboration to achieve the aspirations of the Kingdom and its vision.”
Al-Balawi said: “The signing is the latest of numerous accords Mashroat has signed with various government sectors to spearhead the transformation process. In doing so, we are empowering the project and facilities management offices in public agencies to develop a flexible environment to manage their projects and facilities more efficiently, which in turn increases the effectiveness and enhances the quality of our national infrastructure.”
He added: “This agreement will boost transparency as it allows for monitoring and assessing the performance of project and facilities management offices in the public sector. The resulting improvement in infrastructure will lead to better services to individuals and society as a whole in areas such as transport, housing, urban planning, natural and social environment, health care, economic and educational opportunities and security, thereby improving the overall quality of life in the Kingdom.”
The MoU is an implementation of a royal decree (No. 47004) dated May 31, 2018, pursuant to the Council of Ministers’ resolution stating that public entities shall establish project management offices in cooperation with Mashroat to follow up, coordinate and manage their projects and ensure their delivery.


Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

Updated 27 May 2020

Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

  • Trials are being led locally as an essential means to verify the safety and effectiveness of a new drug
  • Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic

RIYADH: Clinical trials in Saudi Arabia could speed up the adoption of new drugs locally, a pharmaceutical executive has told Arab News.

“Clinical trials have two very big benefits for the Kingdom. Firstly, they provide data in the long run with respect to safety and efficacy, catered specifically to the Saudi population. Secondly, they impact local investment and build healthcare capabilities,” Managing Director of Eli Lilly Dimitri Livadas said..

Lividas further explained that the clinical trial phase of any new treatment is crucial as it represents the stage between the adoption or rejection of a drug. Working with the Ministry of Health and with a presence in the Kingdom for 42 years, the pharmaceutical company began research trials in the country in 2016, consisting of five pre-marketing activities and three monitoring studies for post-marketing.

Lividas added that the trials are being led locally as an essential means to verify the safety and effectiveness of a new drug before it is put to the market and introduced to patients. The majority of these are focused on diabetes, oncology, immunology, and osteoporosis.

“We genuinely believe that our future is here in Saudi Arabia. We continue to make great progress in having a commercial organization in the Kingdom that is fully staffed by Saudi nationals,” said Lividas.

As a biopharmaceutical company, Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic. It recently announced partnership with AbCellera to develop a treatment for the virus and aims to enter into clinical trials this year.

“I salute the Saudi authorities for their strong measures to contain the spread of COVID-19. I think it is an example to the world on how to do this. I would like to also express my gratitude toward all healthcare professionals who are currently on the frontlines, risking their own health to help others," Lividas said.